All In Biotech

Drug Trial Radar · NCT03899155

Pan Tumor Rollover Study

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Aug 9, 2019

Primary completion

Aug 25, 2029

Study completion Aug 25, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Exelixis; Novartis; Clovis Oncology, Inc.; Janssen Pharmaceuticals
First posted
Apr 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Conditions

  • Cancer

Interventions

  • NivolumabDrug

    Specified dose on specified days

  • IpilimumabDrug

    Specified dose on specified days

  • CabozantinibDrug

    Specified dose on specified days

  • TrametinibDrug

    Specified dose on specified days

  • RelatlimabDrug

    Specified dose on specified days

  • Nivolumab + RelatlimabDrug

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • BevacizumabDrug

    Specified dose on specified days

  • TemozolomideDrug

    Specified dose on specified days

  • RucaparibDrug

    Specified dose on specified days

  • DaratumumabDrug

    Specified dose on specified days

  • RegorafinibDrug

    Specified dose on specified days

  • LeucovorinDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • EnzalutamideDrug

    Specified dose on specified days

  • SunitinibDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From Day 1 up to 135 Days after discontinuation of treatment
  2. Incidence of drug related AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
  3. Incidence of AEs leading to DiscontinuationTime frame: From Day 1 up to 135 Days after discontinuation of treatment
  4. Incidence of Serious Adverse Events (SAEs)Time frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment
  5. Incidence of Select AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
  6. Incidence of Immune-Mediated AEsTime frame: From Day 1 up to 135 Days after discontinuation of treatment
  7. Incidence of DeathTime frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment

Locations

410 sites in 38 countries. Site status is shown where the registry gives one.

  • Local Institution - 0220

    Huntsville, Alabama · Completed

  • University of Arizona College of Medicine

    Tucson, Arizona · Withdrawn

  • Innovative Clinical Research Institute

    Lynwood, California · Withdrawn

  • Local Institution

    San Francisco, California · Withdrawn

  • Local Institution - 0099

    San Francisco, California · Completed

  • Local Institution - 0233

    Aurora, Colorado · Completed

  • Local Institution - 0095

    New Haven, Connecticut · Withdrawn

  • Local Institution - 0088

    Washington D.C., District of Columbia · Completed

  • Florida Cancer Affiliates

    Ocala, Florida · Withdrawn

  • Local Institution

    Orlando, Florida · Withdrawn

  • Local Institution - 0024

    Tampa, Florida · Completed

  • Local Institution - 0105

    Chicago, Illinois · Completed

  • Local Institution

    Maywood, Illinois · Withdrawn

  • Local Institution - 0279

    Park Ridge, Illinois · Completed

  • Local Institution - 0186

    Westwood, Kansas · Completed

  • Local Institution - 0165

    Wichita, Kansas · Completed

  • University of Louisville-James Graham Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • Local Institution - 0092

    Baltimore, Maryland · Completed

  • Local Institution - 0039

    Boston, Massachusetts · Completed

  • Dana_Farber Cancer Institute (DFCI)

    Boston, Massachusetts · Recruiting

  • Local Institution - 0081

    Boston, Massachusetts · Withdrawn

  • Local Institution - 0143

    Ann Arbor, Michigan · Completed

  • Local Institution - 0100

    Minneapolis, Minnesota · Completed

  • Local Institution

    St Louis, Missouri · Withdrawn

  • Local Institution - 0205

    Omaha, Nebraska · Completed

  • Local Institution - 0014

    Lebanon, New Hampshire · Completed

  • Local Institution

    Albuquerque, New Mexico · Withdrawn

  • Local Institution - 0128

    Buffalo, New York · Completed

  • NYU Langone Hematology Oncology Associates-Mineola

    Mineola, New York · Recruiting

  • Local Institution

    New York, New York · Withdrawn

  • Local Institution - 0185

    New York, New York · Completed

  • Local Institution - 0202

    New York, New York · Withdrawn

  • Local Institution

    New York, New York · Withdrawn

  • Local Institution - 0204

    Charlotte, North Carolina · Completed

  • Local Institution - 0016

    Durham, North Carolina · Completed

  • Oncology Hematology Care

    Cincinnati, Ohio · Recruiting

  • Local Institution - 0408

    Cincinnati, Ohio · Completed

  • Local Institution

    Cleveland, Ohio · Withdrawn

  • The Ohio University

    Columbus, Ohio · Recruiting

  • Local Institution - 0246

    Tulsa, Oklahoma · Withdrawn

Showing 40 of 410 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.